Last reviewed · How we verify
ENG 120 µg + EE 15 µg intravaginal ring
This intravaginal ring releases etonogestrel (a progestin) and ethinyl estradiol (an estrogen) to prevent ovulation and provide contraception.
This intravaginal ring releases etonogestrel (a progestin) and ethinyl estradiol (an estrogen) to prevent ovulation and provide contraception. Used for Contraception in women of reproductive age.
At a glance
| Generic name | ENG 120 µg + EE 15 µg intravaginal ring |
|---|---|
| Also known as | NuvaRing |
| Sponsor | Organon and Co |
| Drug class | Combined hormonal contraceptive |
| Modality | Small molecule |
| Therapeutic area | Contraception / Women's Health |
| Phase | Phase 3 |
Mechanism of action
The combination of etonogestrel and ethinyl estradiol works synergistically to suppress the luteinizing hormone (LH) surge needed for ovulation, while also thickening cervical mucus and altering the endometrium to prevent fertilization and implantation. The intravaginal ring formulation provides sustained, controlled release of both hormones over a 3-week cycle, offering a non-daily contraceptive option with improved compliance compared to oral formulations.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Headache
- Nausea
- Vaginal irritation or discomfort
- Breast tenderness
- Mood changes
- Breakthrough bleeding or spotting
Key clinical trials
- A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |